| scholarly article | Q13442814 |
| P50 | author | Davis M Vigneault | Q57317751 |
| Mark A Ahlman | Q89233795 | ||
| Veit Sandfort | Q90128193 | ||
| Marissa Mallek | Q117253340 | ||
| David A. Bluemke | Q39818611 | ||
| P2093 | author name string | Nehal N Mehta | |
| Peter Herscovitch | |||
| Roberto Maass-Moreno | |||
| Ahmed Sadek | |||
| Jenny Dave | |||
| Mariana A F Selwaness | |||
| P2860 | cites work | Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study | Q48952305 |
| PET assessment of vascular inflammation and atherosclerotic plaques: SUV or TBR? | Q53024515 | ||
| Progression of renal insufficiency: role of blood pressure | Q69590787 | ||
| Cardiovascular disease | Q73609074 | ||
| Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV | Q85471246 | ||
| Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomograpic imaging | Q87218257 | ||
| A new equation to estimate glomerular filtration rate | Q24651973 | ||
| Heart disease and stroke statistics--2011 update: a report from the American Heart Association | Q29547236 | ||
| Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. | Q33624365 | ||
| Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. | Q33624371 | ||
| Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography | Q33719962 | ||
| Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study | Q33956714 | ||
| Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial | Q34120778 | ||
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 | ||
| Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group | Q36900139 | ||
| Obesity Is Associated With Progression of Atherosclerosis During Statin Treatment | Q37240748 | ||
| Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values | Q37696898 | ||
| Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? | Q37761792 | ||
| Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. | Q38365778 | ||
| Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification | Q38397910 | ||
| Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis | Q38605303 | ||
| Imaging of vasculitis: State of the art. | Q38785564 | ||
| Evaluation of Spleen Glucose Metabolism Using 18F-FDG PET/CT in Patients with Febrile Autoimmune Disease. | Q40086863 | ||
| Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations | Q40091380 | ||
| The prognostic value of baseline (18)F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters. | Q40144137 | ||
| Cost analysis of PET and comprehensive lifestyle modification for the reversal of atherosclerosis | Q43701962 | ||
| Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function. | Q45190282 | ||
| Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. | Q45370639 | ||
| Modeling the excretion of FDG in human kidneys using dynamic PET. | Q46245690 | ||
| Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction | Q47384247 | ||
| FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues | Q48131010 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e0187995 | |
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials | |
| P478 | volume | 12 |
| Q90911186 | Clinical Factors Associated with Time-Specific Distribution of 18F-Fluorodeoxyglucose in Large-Vessel Vasculitis | cites work | P2860 |
Search more.